According to the publicly available data from TCGA, the prevalence of ADCK2 pathogenetic or unknown variants in most cancers is 0%, rarely above 1%, with the maximum pathogenetic or unknown variant frequencies observed in endometrial carcinomas and in rare uterine carcinosarcomas, up to 3.5% of cases [43, 44]. This evidence concerns the gene ADCK2 and cancer.